Immunic (IMUX) Projected to Announce Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.7852) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 19, 2026 at 9:30 AM ET.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.36. On average, analysts expect Immunic to post ($3.69) EPS for the current fiscal year and ($2.61) EPS for the next fiscal year.

Immunic Stock Performance

Shares of NASDAQ IMUX opened at $8.04 on Wednesday. Immunic has a one year low of $5.06 and a one year high of $17.43. The business has a 50-day moving average price of $9.06 and a two-hundred day moving average price of $11.50.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on IMUX shares. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Immunic in a research report on Thursday, September 10th. Roth Capital reaffirmed a “buy” rating on shares of Immunic in a research report on Tuesday, September 1st. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, August 26th. Finally, Wedbush reiterated an “outperform” rating and issued a $45.00 target price on shares of Immunic in a research report on Thursday, September 10th. Four research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Immunic currently has an average rating of “Buy” and an average target price of $35.43.

About Immunic

Immunic, Inc. (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on treatments designed to address significant unmet needs while potentially offering convenient alternatives to injectable or infusion-based therapies. Immunic’s lead product candidate is vidofludimus calcium, formerly known as IMU-838. It is a selective oral inhibitor of dihydroorotate dehydrogenase (DHODH) being developed for multiple sclerosis, including relapsing and progressive forms of the disease.